Pharma & Biotech Insights, Interviews & Features
Today's issue
Refine Search
Biotechnology
During the whole of 2022, merger and acquisition (M&A) activity in the pharma and biotech sector showed a slight improvement on 2021, when it fell to a decade low of just 92 deals, with a total number of 109 (See table below). 2 January 2023
Generics
A growing number of key starting materials (KSMs) and active pharmaceutical ingredients (APIs) coming into India have become 25% to 35% more expensive as reports of Covid infections spiral out of control in China, squeezing margins and increasing drug prices. The Indian government's production linked incentive (PLI) scheme for the promotion of domestic manufacturing of critical KSMs, drug intermediates (DIs) and APIs is soon set to come to the aid of many domestic players, reports The Pharma Letter’s India correspondent. 29 December 2022
Pharmaceutical
Russia plans to localize production of a number of vaccines for the treatment of certain serious diseases in the next several years, according to recent statements by some senior officials of the Russian Ministry of Health and local media. 28 December 2022
Pharmaceutical
The volume of drug production in Russia is steadily growing this year despite the ever-tightening sanctions regime and international isolation of Russia, according to recent statements by some leading local pharma analysts and the Russian media, reports The Parma Letter’s local correspondent. 21 December 2022
Pharmaceutical
Last month, privately-held Swiss firm Ferring achieved a notable scientific first. 21 December 2022
Pharmaceutical
Psychedelics will soon be treating a mental health patient near you. 17 December 2022
Generics
The Russian government together with some leading domestic financial corporations will provide support to domestic producers of active pharmaceutical ingredients (APIs) that will primarily be in the form of provision of preferential loans and other benefits for them, reports The Pharma Letter’s local correspondent. 15 December 2022
Biotechnology
As the year draws to a close, this article presents some of the wins of the orphan drug community in terms of US FDA approvals, while highlighting challenges faced by the sector and looking ahead to the expectations of the next year. 15 December 2022
Pharmaceutical
An analysis of how - and why - ophthalmology is increasingly on pharma and investors' radar as a new growth area. 8 December 2022
Biotechnology
Earlier this month, US President Biden told a Carlsbad, Calif. audience that America’s future rests on major breakthroughs in technology and science. “Other countries are closing in fast,” he elaborated. “The CHIPS and Science Act sets us on a path to move up again.” 8 December 2022
Pharmaceutical
The crisis in the Russian pharmaceutical sector is deepening as the country’s Ministry of Health has officially called on the regions to form a four-month reserve of drugs, which is mainly due to the possible interruptions in their supplies from abroad, reports The Pharma Letter’s local correspondent. 8 December 2022
Biotechnology
Mucopolysaccharidosis type III (MPS III), also known as Sanfilippo syndrome, is a lysosomal storage disorder that affects fetal brain development. It is caused by the absence of enzymes responsible for breaking down a heparan sulphate, which belongs to a group of complex sugars known as glycosaminoglycans.1,2 Lack of these enzymes leads to the accumulation of the sugar in the cells of the central nervous system (CNS), which in turn leads to developmental problems. 1 December 2022
Pharmaceutical
An Expert View from Neelam Patel, chief executive of London life sciences cluster organization MedCity, which led the recent UK delegation to BioJapan 2022, exploring why Japan is such an important partner for the UK and future areas of opportunity. 29 November 2022
Generics
The Russian drugmaker PSK Pharma has launched the production of tofacitinib – a generic version of Pfizer’s Xeljanz/Jaquinus drug, reports The Pharma Letter’s local correspondent. 28 November 2022
Pharmaceutical
The outcome of the recent midterm elections in the USA surprised many by returning a Democrat-led Senate, preventing Republicans from gaining control of the next Congress. We look at the consequences for pharma and biotech. 28 November 2022
Generics
Several Indian pharmaceutical companies are facing the dual challenges of antitrust investigations and being sued by multinational pharmaceutical companies. There has been an increase in probes by the US regulator for possible market failures, such as failure to follow good manufacturing practices and deviations from the regulatory path, in the past few months, with multiple cases scorching the growth plans of Indian drug companies, reports The Pharma Letter’s India correspondent. 28 November 2022
Pharmaceutical
Representatives of the Russian patient community have warned about the shortage of the antiretroviral drug Eviplera (rilpivirine/tenofovir/emtricitabine), the most popular and most expensive combination drug for the treatment of HIV on the domestic market, reports The Pharma Letter’s local correspondent. 22 November 2022
Biotechnology
Investing in early-stage multicenter trials is imperative to achieve global commercialization for Chinese biotechs, but a US site may not be necessary, said speakers at the Chinatrials meeting held in Shanghai earlier this month. 21 November 2022
Generics
As Indian drugmakers cry foul on not receiving an appropriate "incentive for incremental innovation," the government and the domestic pharmaceutical industry are to sit together to iron out the kinks on a pricing mechanism for drugs that are going off patent, reports The Pharma Letter’s India correspondent. 15 November 2022
Pharmaceutical
The demand for insulin in Russia is steadily growing, which provides some opportunities for global majors operating in this market segment, reports The Pharma Letter’s local correspondent. 15 November 2022
Generics
Indian markets are abuzz with a singular refrain. Donald Trump's Presidency of the United States is set to open new opportunities for India, especially in the pharmaceutical sector. 8 November 2024
Biotechnology
According to UNICEF's State of the World's Children 2023 report, in Latin America
and the Caribbean, 6.8 million children did not benefit from vaccination during the
time of the pandemic and in the following two years, progress has not been as
expected either. 7 November 2024
Biotechnology
An Expert View from Cumulus Oncology about its innovative business model, which is all about improving the efficiency of drug R&D. 7 November 2024
Generics
Indian drugmaker Aurobindo Pharma has taken on the might of China in terms of Penicillin G pricing, and is doing so by leveraging a fully integrated production process at its new plant. Anticipating the price erosion of Penicillin G, the company has put up an integrated plant from scratch. 31 October 2024
Pharmaceutical
Life science investors can be divided into two groups: those who bought Novo Nordisk stock before GLP-1s hit the big time, and those who wish they had. 23 October 2024
Biotechnology
As India's bioeconomy soars to a remarkable valuation of $151 billion, the government's Biotechnology Industry Research Assistance Council (BIRAC) has underscored the critical need for innovation and private sector investment to unlock further growth. 21 October 2024
Pharmaceutical
An Expert View from Nick Petschek, Managing Director EMEA, Kotter International. 18 October 2024
Biotechnology
Where once the state of play in the cell and gene therapy space was mostly limited to hope and hype around what might be to come, this is increasingly being replaced by action, on-market therapies and genuine expectation of reaching patients—provided companies can avoid some of the sector’s notorious pitfalls. 16 October 2024
Biotechnology
Antibody-drug conjugates (ADCs) represent a transformative class of cancer therapy that combine the targeting ability of antibodies with the cell-killing potential of cytotoxic drugs. 15 October 2024
Biotechnology
At last month’s European Academy of Dermatology and Venereology (EADV) congress in Amsterdam, Novartis presented new early and long-term Phase III data for remibrutinib in chronic spontaneous urticaria (CSU). 14 October 2024
Biotechnology
India's new Biotechnology Research Innovation and Entrepreneurship Development (Bio-RIDE) scheme is a significant step towards consolidating and advancing the country's biotechnology initiative. 7 October 2024
Pharmaceutical
F2G’s September $100m funding round provides the company with crucial funds to
renavigate approval of its lead drug, olorofim. The substantial financing also
highlights the paucity of novel antifungal products in the clinic. 3 October 2024
Pharmaceutical
Timing can be crucial in biotech, and any company that can help optimize radiopharmaceuticals to fight cancer is likely to a hot property right now, given the recent popularity of the field among investors and drugmakers. 2 October 2024
Pharmaceutical
As stakeholders in the pharmaceutical industry, we all have a responsibility to ensure life-saving treatments promptly and safely reach patients regardless of where they live. To this end, by integrating early access programs and other less conventional strategies into a company’s business model for drug distribution, patients who are suffering from life-threatening conditions can gain access to needed treatments in regions where there is a lack of drug accessibility, while at the same time offering benefits to pharmaceutical companies. 2 October 2024
Pharmaceutical
The Russian government has finalized the rules for granting preference to domestic drugs in public procurements, which will come into force in 2025. 1 October 2024
Pharmaceutical
A Feature on M&A, licensing and partnerships hotting up in inflammatory diseases as new targets present new opportunities for future growth. 30 September 2024
Pharmaceutical
India is set to complete 50 new greenfield pharma manufacturing plants in the next two years under its Production-linked Incentive (PLI) scheme for pharma and medical devices. 30 September 2024
Generics
The number of clinical trials of new drugs in Russia is steadily declining, which could be mainly related with the overall reduction of investment activities in the local pharmaceutical market, reports The Pharma Letter’s local correspondent. 30 September 2024
Pharmaceutical
Scarcely anything unites lawmakers in America these days, but the ostensible iniquities of Big Pharma could be a rare exception. 22 September 2024
Pharmaceutical
An Expert View from Leslie Orne, president and chief executive, Trinity Life Sciences. 20 September 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze